Valuation: APOE THERPAR

Market Cap 10.19B 9.14B 8.35B 7.62B 14.36B 958B 14.81B 101B 40.13B 511B 38.23B 37.41B 1,613B P/E 2027 *
-
P/E 2028 * -
Enterprise Value 9.29B 8.33B 7.62B 6.95B 13.1B 873B 13.51B 91.81B 36.61B 466B 34.88B 34.13B 1,471B EV / Sales 2027 *
-
EV / Sales 2028 * -
Free-Float
97.31%
Yield 2027 *
-
Yield 2028 * -
1 day-0.01%
3 months+0.43%
6 months+59.77%
Current year+78.95%
Current year 60.35
Extreme 60.35
135.09
1 year 55.58
Extreme 55.5846
135.09
3 years 14.19
Extreme 14.19
135.09
5 years 14.19
Extreme 14.19
135.09
10 years 14.19
Extreme 14.19
135.09
Manager TitleAgeSince
Director of Finance/CFO 60 01/01/2023
Chief Tech/Sci/R&D Officer - 01/05/2023
Chief Tech/Sci/R&D Officer 41 01/09/2022
Date Insider Type Main position Quantity % Market Cap. Importance
3/9/26
Fairmount Funds Management LLC
Issuer saleCompany -340,855 0.5480%
3/9/26 Issuer sale

Director

-48,780 0.0784%
3/9/26
Venrock Associates
Issuer saleCompany -2,115,853 3.4016%
Change 5-day change 1-year change 3-year change Capi.($)
-0.01%-.--%+145.60%+682.11% 10.19B
-4.83%+3.51%+53.62%+61.75% 65.94B
-1.34%+2.98%+24.79%+100.18% 56.53B
+0.02%+1.07%+10.63%+76.66% 56.88B
+5.09%+9.89%+22.45%+107.48% 46.49B
+2.62%+1.68%+28.91%+37.01% 44.8B
+8.24%+0.51%+213.26%+792.66% 41.59B
-1.86%+10.13%+26.82%+53.22% 35.35B
-2.97%-9.84%+88.86%+76.17% 33.29B
-2.18%+7.06%+36.06%-4.95% 24.92B
Average +0.28%+2.94%+65.10%+198.23% 41.6B
Weighted average by Cap. +0.20%+3.32%+55.38%+156.16%

Financials

2027 *2028 *
Net sales - -
Net income -372M -334M -305M -278M -525M -34.98B -541M -3.68B -1.47B -18.66B -1.4B -1.37B -58.92B -497M -446M -407M -372M -701M -46.71B -723M -4.91B -1.96B -24.92B -1.87B -1.83B -78.68B
Net Debt - -
Projected Income Statement - Annual - APOE THERPAR
Logo APOE THERPAR
Apogee Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is advancing novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. APG777, the Company’s most advanced program, is being initially developed for the treatment of AD. With four validated targets in its portfolio, it is seeking to achieve efficacy and dosing through monotherapies and combinations of its novel antibodies. Its most advanced programs are APG777, APG990, APG333, and APG808. APG990 is an SQ extended half-life mAb that utilizes advanced antibody engineering to target OX40L. APG333 is a fully human mAb against thymic stromal lymphopoietin (TSLP). APG808 is an SQ extended half-life mAb targeting IL-4Ra. APG279 is for the dual inhibition of OX40L and IL-13.
Employees
261
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - APOE THERPAR
  1. Stock Market
  2. Stocks
  3. APGE Stock